LP
TRVI icon

Longaeva Partners’s Trevi Therapeutics TRVI Stock Holding History

Longaeva Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$54.7K – 90
2025
Q2 		$54.7K Buy
+10,000
New +$62.2K 0.01% 54

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Longaeva Partners's TRVI Position: Q3 2025 in Review

Longaeva Partners sold out of Trevi Therapeutics (TRVI) in Q3 2025, closing a stake of 10,000 shares — an estimated $54.7K sold.

Longaeva Partners first reported a position in TRVI in Q2 2025 and held it in 1 quarter. The position peaked at $54.7K in Q2 2025. 164 funds tracked by Wall St. Rank hold TRVI as of Q3 2025.

  • Longaeva Partners reported no remaining Trevi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Longaeva Partners sold 10,000 Trevi Therapeutics shares in Q3 2025, an estimated $54.7K.
  • Longaeva Partners first reported a position in Trevi Therapeutics in Q2 2025 and held it in 1 quarter.
  • Longaeva Partners's Trevi Therapeutics position peaked at $54.7K in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2025.

Based on Longaeva Partners's 13F filing for Q3 2025, filed 14 Nov 2025.